The News
Cobion acquired by Internet Security Systems
16/02/2004
Cobion AG, a pioneer in content security, has been acquired by Internet Security Systems, Inc. (Nasdaq: ISSX), a US-based leader in internet security systems. The price was €26 million.
Sofinnova Partners invested in Cobion, which was founded in Kassel, Germany, in 1997, at the invitation of Wellington Partners in October 2003. Cobion was the first investment ever made by Sofinnova Partners in the IT sector in Germany. The sale of Cobion is a sign of a recovery in mergers and acquisitions activity in the software industry. By joining forces, the two leading players in the security business will be able to deliver advanced security solutions in the fast-growing content-filtering and anti-spam security sectors. The global market for content security is expected to reach $ 1.5 billion in 2006. ISS acquired Cobion for its intelligent content analysis technology, spam and Web content filtering databases, and its robust research infrastructure. The Cobion technology will be immediately assimilated into the ISS Proventia ™ product family.
2004
- 21/01/2004
- 21/01/2004
- 28/01/2004
- 26/01/2004
- 26/01/2004
- 29/01/2004
-
29/01/2004
Sofinnova Partners investit dans InfraWorlds, société à fort potentiel
- 09/02/2004
- 09/02/2004
-
16/02/2004
Cobion acquired by Internet Security Systems
- 25/02/2004
- 25/02/2004
-
26/02/2004
Esmertec gains a worldwide leadership role in fast growing mobile Java™ markets
- 24/02/2004
- 24/02/2004
-
23/02/2004
SOFINNOVA earmarks €85 million to accelerate activity in European wireless market
- 04/03/2004
- 08/03/2004
- 17/03/2004
- 08/03/2004
- 18/03/2004
- 29/03/2004
- 29/03/2004
-
07/04/2004
Esmertec™ provides Time Warner Cable with JVM solution for the OCAP Market
- 06/04/2004
- 06/04/2004
- 20/04/2004
- 21/04/2004
- 27/04/2004
-
03/05/2004
Vidiom Systems Selects Esmertec™ to provide the JVM solution for its OCAP Products
-
05/05/2004
Georges Haas, Ph.D., Joins Ingenium’s Supervisory Board Munich, Germany, May 5, 2004
-
10/05/2004
Faust raises 16 million euros to further develop its product candidates
-
10/05/2004
Faust Pharmaceuticals lève 16 M d’euros pour développer ses produits en clinique
-
03/05/2004
Saegis Pharmaceuticals Begins Phase II Clinical Trial of SGS742 for Alzheimer’s Disease
- 28/04/2004
-
12/05/2004
Ingenium Acquires Pivotal Patents for INGENOtypingTM Platform
-
17/05/2004
Addex Pharmaceuticals Completes Largest ever European Biotech Series B Fund Raising
- 19/05/2004
- 25/05/2004
- 10/06/2004
- 07/06/2004
- 22/06/2004
- 07/06/2004
- 14/06/2004
-
14/06/2004
TRISENOX® Produces Hematologic Responses in 27 Percent of MDS Patients
-
22/06/2004
Esmertec to demonstrate new breakthrough Java™ Solution – Jbed™ Advanced during JavaOne 2004
- 22/06/2004
-
28/06/2004
Esmertec’s Java™ Virtual Machine (JVM) solution for mobile phones is selected by Panasonic
- 01/07/2004
- 23/06/2004
-
06/07/2004
Atomz Named to Second-Annual AlwaysOnTM List of Top 100 Private Companies
- 30/06/2004
-
12/07/2004
Qosmos reçoit un premier tour de financement de Sofinnova Partners
-
12/07/2004
Qosmos receives a first round of financing from Sofinnova Partners
-
07/07/2004
Esmertec ouvre un centre d'assistance clientèle et de test à Taipei (Taiwan)
-
07/07/2004
Esmertec is opening Customer Support and Testing Centre in Taipei, Taiwan
-
19/07/2004
Ablynx and Procter&Gamble form nanobody drug discovery and development partnership
- 22/07/2004
- 20/07/2004
-
22/07/2004
Esmertec welcomes Michel Bon, Former CEO and Chairman of France Telecom, to its Board
-
26/07/2004
Cell Therapeutics, Inc. Completes Enrollment in Third Pivotal Trial of XYOTAX™ in Lung Cancer
- 26/07/2004
-
28/07/2004
Diatos Elected Among the Top 15 Emerging Biotech Companies of 2004
-
30/07/2004
6WIND emporers customers and partners with a further commitment to quality
-
02/08/2004
Les plus hautes performances Java jamais atteintes sur cœur de MIPS32 24Kc
-
02/08/2004
Highest Java™ Performance Achieved by the MIPS32® 24Kc™ Core
- 27/07/2004
- 27/07/2004
- 16/08/2004
-
09/08/2004
"Euronext n'a pas la place financière qu'il mérite" Jean-Bernard Schmidt - Les Echos 9 Août 2004 -
-
30/08/2004
Tony Reis, l’ancien CEO de Swisscom, rejoint le Conseil d’Administration d’Esmertec
-
30/08/2004
Tony Reis, Former CEO of Swisscom, joins Esmertec’s Board of Directors
-
24/08/2004
Enfora partners with Esmertec to enable wireless Java technology in their GSM/GPRS OEM devices
-
24/08/2004
Enfora se rapproche d’Esmertec pour intégrer la technologie Java dans ses terminaux GSM/GPRS
-
16/08/2004
Intransa secures twenty five million dollars in series D funding
-
06/09/2004
Sensitive Object secures 2 million € Series A financing round from Sofinnova Partners
- 06/09/2004
-
08/09/2004
Oxxius reçoit un premier financement de 2,4 millions d'euros de Sofinnova Partners
-
14/09/2004
Le Dr Ulrich Schumacher rejoint le Conseil d’Administration d’Esmertec
-
08/09/2004
Oxxius receives 2.4 million euros from Sofinnova Partners in first round of financing
-
14/09/2004
Dr. Ulrich Schumacher joins Esmertec as a Member of the Board of Directors
- 20/09/2004
- 23/09/2004
-
23/09/2004
France Telecom selects Esmertec as technology partner for its embedded Java platforms
- 30/09/2004
- 30/09/2004
-
26/10/2004
Esmertec lève CHF 23.5 Millions par le biais d’obligations convertibles
-
26/10/2004
Esmertec raises CHF 23.5 Million from convertible note to fund growth
-
26/10/2004
Intransa annouces IP5500 - The industry's next-generation modular IP san solution for the mid-market
-
10/11/2004
Varioptic Selected Most Innovative Company of the Year for Its Liquid Lenses
-
10/11/2004
Varioptic élue Entreprise Innovante de l’année pour ses lentilles liquides
- 18/11/2004
-
18/11/2004
Esmertec Establishes Strategic Relationship with Mitsui & Co.
- 17/11/2004
-
22/11/2004
Ablynx appoints Edwin Moses as chairman of the board of directors
-
23/11/2004
Sendo choisit la solution Java d’Esmertec’s pour ses téléphones mobiles
-
23/11/2004
Sendo has chosen Esmertec’s Java solution for its mobile phones
- 23/11/2004
- 06/12/2004
-
05/12/2004
TRISENOX® Produces Hematologic Responses in 30 Percent of Patients with Higher-Risk MDS
-
09/12/2004
Esmertec to Integrate Hybrid’s OpenGL ES based Graphics Solutions into its Jbed Solution
-
16/12/2004
Diatos moves its lead drug, DTS-201, toward clinical trials in Europe
- 23/12/2004
- 16/12/2004
- 01/11/2004
-
16/12/2004
Esmertec to further secure mobile Java content with SATSA-based implementation from Gemplus
-
16/12/2004
Esmertec sécurise les contenus des mobiles Java avec l’implémentation SATSA de Gemplus
